Does assessment of late gadolinium enhancement improve risk stratification in hypertrophic cardiomyopathy based on current guidelines?
The 2022 ESC risk model outperforms the 2014 model in hypertrophic cardiomyopathy, and the addition of late gadolinium enhancement further improves risk stratification.
The 2022 ESC model performed better than the 2014 ESC model with especially improved sensitivity. LGE enabled further risk stratification based on current guidelines.
Wang et al. (Thu,) studied this question.